Prevalence and spectrum of diabetic peripheral neuropathy and its correlation with insulin resistance - An experience from eastern India - Majumdar, Manidipa; Banerjee, Mainak; Sengupta, Jinesh; Deb, Soudeep; Jana, Chanchal Kr.; Roy, Biman Kanti (medRxiv, 2020)
AIMS Diabetes mellitus is a public health problem worldwide, with diabetic neuropathy (DN) being a common complication. Studies indicate that, neurons can develop insulin resistance (IR) and cannot respond to the neurotrophic properties of insulin. Although studies exist on the relation between DN and glycemic exposure index (GEi), papers about correlation of DN with IR is rare. This study focused on the prevalence of neuropathies in DM patients and usefulness of IR as a marker of DN.METHODS A cross sectional observational study was done. All patients satisfying American Diabetes Association criteria and none of the exclusion criteria were included. Total sample size was 142. Main parameters studied were glycemic status, neurological examination and nerve conduction study findings. Dyck grading was used for severity of distal symmetric polyneuropathy (DSPN). For statistical analysis, logistic and ordinal logistic regressions were used as appropriate.RESULTS 34.5% of the sample had DN, the commonest type being DSPN (72.9%). The study population was equally divided in terms of gender and 88.7% were type 2 diabetic. About 62.5% neuropathic cases were asymptomatic. Occurrence of DN correlated significantly with duration of diabetes, FBS and IR. Age, when adjusted for other risk factors was not significantly correlated to neuropathy. The severity of DSPN correlated significantly with GEi but not with IR.CONCLUSIONS The prevalence of neuropathy was found to be similar to earlier western studies. This paper further establishes IR as a significant predictor for existence of DN, but it may not affect the progress of the neuropathy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was used.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be made available by authors on request.